Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Talking Smart Hospitals With Two Companies Working To Make Them A Reality

Executive Summary

“The sky’s the limit in terms of what’s possible within smart hospitals,” according to Brad Genereaux, global lead of health care alliances at NVIDA. He and Roger Lam, director of engineering at hardware manufacturers MBX systems, spoke to Medtech Insight about the potential of smart hospitals and what needs to be done to create them.

You may also be interested in...



Digital Health Roundup: Cardiology, Mobility-Related Agetech, Smart Hospitals, Awards, Fund-Raising

In this month’s Digital Health Roundup, Medtech Insight’s Reed Miller talks about Biotronik’s and AliveCor’s partnership, Marion Webb profiles three agetech companies, and Barnaby Pickering talks Swiss medtech awards and smart hospitals.

Liquid Biopsy Revolutionizing Cancer Care, But Costs Continue To Inhibit Global Potential

Liquid biopsy represents potential advantages over traditional approaches to cancer surveillance, treatment selection and recurrence monitoring. But one size does not fit all, requiring tailored solutions for less developed markets.

Minute Insight: Indigo Diabetes Starts Human Trial Of Subcutaneous Glucose Monitor

The company has enrolled the first patient in the second human trial of its implantable metabolite monitoring system, which it expects could change the game for blood glucose measurement.

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT145736

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel